TY - JOUR
T1 - A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies
AU - Chan, Alexandre
AU - Cameron, Michael C.
AU - Garden, Benjamin
AU - Boers-Doets, Christine B.
AU - Schindler, Katja
AU - Epstein, Joel B.
AU - Choi, Jennifer
AU - Beamer, Laura
AU - Roeland, Eric
AU - Russi, Elvio G.
AU - Bensadoun, René Jean
AU - Teo, Yi Ling
AU - Chan, Raymond J.
AU - Shih, Vivianne
AU - Bryce, Jane
AU - Raber-Durlacher, Judith
AU - Gerber, Peter Arne
AU - Freytes, César O.
AU - Rapoport, Bernardo
AU - LeBoeuf, Nicole
AU - Sibaud, Vincent
AU - Lacouture, Mario E.
PY - 2015/8
Y1 - 2015/8
N2 - Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL. Methods: A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments. Results: Thirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16
AB - Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL. Methods: A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments. Results: Thirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16
KW - Dermatologic adverse events
KW - Health-related quality of life
KW - Patient-reported outcomes
KW - Targeted cancer therapy
UR - http://www.scopus.com/inward/record.url?scp=84933183142&partnerID=8YFLogxK
U2 - 10.1007/s00520-014-2564-x
DO - 10.1007/s00520-014-2564-x
M3 - Article
C2 - 25564221
AN - SCOPUS:84933183142
SN - 0941-4355
VL - 23
SP - 2231
EP - 2244
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 8
ER -